483
Patrick S. Lynch, MDFDA 483 - Patrick S. Lynch, MD - April 19, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Patrick S. Lynch, MD in Houston, TX, revealed significant deficiencies in clinical trial conduct. Observations included failures to promptly report serious adverse events to the sponsor, non-adherence to the study protocol regarding subject assessments, and improper documentation of informed consent forms. These findings indicate a need for improved oversight and adherence to regulatory requirements for clinical investigations.
Open in Dashboard
ID · 003eec55-fcfa-42e6-bd60-2cda7f85f215